Pfizer's second-quarter results were better than expected. The drugmaker will still face some near-term uncertainty. However, its long-term prospects look attractive, especially at current levels. 10 ...

Wondering how well you'd have done if you'd invested in pharmaceutical giant Pfizer (PFE 0.06%) three years ago and hung on?